ESCMID Global 2026: repeat vaccination with mRNA-1010 safe and effective
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference in Munich, Germany, late-breaking data on …
Post
-
-
Paradigm Health debuts post-marketing study tool for routine care integration
Clinical trials technology specialist Paradigm Health has introduced a new, late-phase clinical evidence generation platform, which sets out to streamline …
-
Tenvie doses first subject in Phase I TNV108 trial for peripheral neuropathies
Tenvie Therapeutics has dosed the first participant in its Phase I clinical trial of TNV108 to treat peripheral neuropathies. The trial …
-
AstraZeneca’s COPD drug gains third Phase III win
AstraZeneca’s tozorakimab has shown benefit in a third Phase III trial in chronic obstructive pulmonary disorder (COPD). In the MIRANDA trial …
-
Atsena secures DMC approval for LIGHTHOUSE trial
Atsena Therapeutics is set to proceed with the pivotal Part C cohort of its Phase I/II/III LIGHTHOUSE trial of ATSN-201 …
-
AstraZeneca’s COPD drug gains third Phase III win
AstraZeneca’s tozorakimab has shown benefit in a third Phase III trial in chronic obstructive pulmonary disorder (COPD). In the MIRANDA trial …
-
Atsena secures DMC approval for LIGHTHOUSE trial
Atsena Therapeutics is set to proceed with the pivotal Part C cohort of its Phase I/II/III LIGHTHOUSE trial of ATSN-201 …
-
AAN 2026: Phase III success for azetukalner in focal epilepsy paves approval path
On 19 April, at the 2026 American Academy of Neurology (AAN) meeting, in the late-breaking science session, Xenon Pharmaceuticals announced …
-
Novo Nordisk to seek oral sickle cell therapy approval after Phase III victory
A Phase III trial of Novo Nordisk’s once-daily tablet has met both co-primary endpoints, reducing vaso-occlusive crises (VOC) and increasing …
-
Trump backs psychedelics for mental health in new executive order
US President Donald Trump has signed an executive order focused on accelerating the route of psychedelics to the market, adding …
-
Akamis Bio reports early data from NG-350A Phase Ib trial
Akamis Bio has announced encouraging initial findings from its ongoing Phase Ib trial of the oncolytic immunotherapy NG-350A in combination …
-
The future of quality in CDMOs: The five-stage journey to an advanced Pharmaceutical Quality System (PQS)
In the first part of our Q&A with Grace Breen, SVP, Quality, Sharp, we explored valuable insights derived from her …
-
Four ways to build a secure and scalable CGT distribution network
CGTs offer potentially life-changing treatment for a broad spectrum of complex diseases, from genetic conditions to cancers. The pace of …
-
Agenus announces Phase II results from gastroesophageal cancer therapy
Agenus has reported results from a Phase II trial, evaluating the combination of botensilimab (BOT), balstilimab (BAL), and agenT-797 alongside …
-
Roche to launch global study of Elevidys following EU rejection
Roche will launch a global Phase III trial of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec), after …
